Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study).

[1]  N. Meda,et al.  Impact of Introducing Hepatitis B Birth Dose Vaccines into the Infant Immunization Program in Burkina Faso: Study Protocol for a Stepped Wedge Cluster Randomized Trial (NéoVac Study) , 2021, Vaccines.

[2]  M. Lemoine,et al.  Coverage and Timeliness of Birth Dose Vaccination in Sub-Saharan Africa: A Systematic Review and Meta-Analysis , 2020, Vaccines.

[3]  Minal K. Patel,et al.  Selective Hepatitis B Birth-Dose Vaccination in São Tomé and Príncipe: A Program Assessment and Cost-Effectiveness Study. , 2019, The American journal of tropical medicine and hygiene.

[4]  C. Staton,et al.  Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies , 2019, Conflict and Health.

[5]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[6]  M. Hellard,et al.  Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. , 2018, The Lancet. Global health.

[7]  K. Claxton,et al.  Discounting in Economic Evaluations , 2018, PharmacoEconomics.

[8]  H. Tinto,et al.  High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies , 2018, BMC Public Health.

[9]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[10]  Uchenna Okonkwo,et al.  Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. , 2017, The lancet. Gastroenterology & hepatology.

[11]  A. Traore,et al.  Barriers to Linkage to Care for Hepatitis B Virus Infection: A Qualitative Analysis in Burkina Faso, West Africa. , 2016, The American journal of tropical medicine and hygiene.

[12]  Karl Claxton,et al.  Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  T. Hallett,et al.  Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.

[14]  A. Funk,et al.  Systematic review with meta‐analysis: the risk of mother‐to‐child transmission of hepatitis B virus infection in sub‐Saharan Africa , 2016, Alimentary pharmacology & therapeutics.

[15]  U. d’Alessandro,et al.  Barriers to timely administration of birth dose vaccines in The Gambia, West Africa , 2016, Vaccine.

[16]  H. Whittle,et al.  Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia , 2015, Gut.

[17]  A. Hall,et al.  Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case–control study in The Gambia , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[18]  M. Falagas,et al.  Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. , 2015, The Journal of antimicrobial chemotherapy.

[19]  H. Whittle,et al.  Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program , 2014, BMC Infectious Diseases.

[20]  A. Hall,et al.  Association of Early Age at Establishment of Chronic Hepatitis B Infection with Persistent Viral Replication, Liver Cirrhosis and Hepatocellular Carcinoma: A Systematic Review , 2013, PloS one.

[21]  H. Whittle,et al.  Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster Dose , 2013, PloS one.

[22]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  C. Klingler,et al.  Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. , 2012, Vaccine.

[24]  Y. Liaw,et al.  Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. , 2012, Journal of hepatology.

[25]  P. Revill,et al.  HBV Genotypes: Relevance to Natural History, Pathogenesis and Treatment of Chronic Hepatitis B , 2011, Antiviral therapy.

[26]  H. Whittle,et al.  Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[27]  B. Gessner,et al.  A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Côte d'Ivoire. , 2008, Vaccine.

[28]  E. Messou,et al.  Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. , 2008, World journal of gastroenterology.

[29]  Fangjun Zhou,et al.  A mathematical model to estimate global hepatitis B disease burden and vaccination impact. , 2005, International journal of epidemiology.

[30]  H. Hsu,et al.  Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination , 2004, Hepatology.

[31]  N. Meda,et al.  [HIV infection and hepatitis B co-infection: survey of prevalence in pregnant women in Bobo Dioulasso, Burkina Faso]. , 2001, Revue medicale de Bruxelles.

[32]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.

[33]  W. Edmunds,et al.  Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areasr , 1996, Epidemiology and Infection.

[34]  A J Hall,et al.  The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[35]  B. McMahon,et al.  Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. , 1992, The American journal of medicine.

[36]  D. Ilboudo,et al.  [Mother-to-child transmission of hepatitis B virus, in Ouagadougou, Burkina Faso]. , 2002, Medecine tropicale : revue du Corps de sante colonial.